What SEC filings does BioMarin Pharmaceutical Inc. submit to the SEC?

BioMarin Pharmaceutical Inc. (BMRN) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about BMRN?

A Form 4 for BMRN discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from BioMarin Pharmaceutical Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for BMRN?

The 10-K is BioMarin Pharmaceutical Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all BMRN SEC filings directly on EDGAR?

You can view all historical BioMarin Pharmaceutical Inc. filings on the SEC EDGAR company page for BMRN. Each filing card on this page links directly to the original SEC document.

How often does BioMarin Pharmaceutical Inc. file with the SEC?

BioMarin Pharmaceutical Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling BMRN shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

BMRN SEC Filing News — BioMarin Pharmaceutical Inc.

Latest SEC filings for BioMarin Pharmaceutical Inc. (BMRN) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-06.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic pep…

Sector: Healthcare Industry: Biotechnology Market Cap: $10.6B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for BMRN currently lean bearish. Of the 20 filing records displayed, 1 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

BMRN Filing Activity Snapshot 2026-06-04 — 2026-10-06

Insider Transactions (Form 4)

0 buys vs 1 sell

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.16M

Davis George Eric · 2026-09-02

17,557 shares · Form 144

Form 144 Notices

Proposed insider sale filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for BioMarin Pharmaceutical Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 7 compensation award, 1 open-market sale and 1 tax withholding. 1 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×1: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Tax withholding ×1: Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Form 4 Tax withholding Tax / Compensation Filing 2026-10-01

BMRN insider Form 4 filed for equity award, exercise, or tax withholding

Friberg Gregory R (EVP, Chief R&D Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	4,086	$60.00	$245.2K

Filing: Form 4 (Insider Transaction) Insider: Friberg Gregory R (EVP, Chief R&D Officer) Shares: 4,086

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-14

BMRN insider Form 4 filed for equity award, exercise, or tax withholding

Plenge Robert M (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,140	—	—

Filing: Form 4 (Insider Transaction) Insider: Plenge Robert M (Director) Shares: 6,140

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-03

BMRN insider Davis George Eric (EVP, Chief Legal Officer) sold 17,557 shares (~$1.16M)

Davis George Eric, listed as EVP, Chief Legal Officer at BIOMARIN PHARMACEUTICAL INC, reported an open-market sale of 17,557 BMRN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	17,557	$66.28	$1.16M

Filing: Form 4 (Insider Transaction) Insider: Davis George Eric (EVP, Chief Legal Officer) Shares: 17,557 Est. Value: $1.16M

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-04

BMRN insider Form 4 filed for equity award, exercise, or tax withholding

Countouriotis Athena (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	7,490	—	—

Filing: Form 4 (Insider Transaction) Insider: Countouriotis Athena (Director) Shares: 7,490

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-04

BMRN insider Form 4 filed for equity award, exercise, or tax withholding

Walbert Timothy P (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	7,490	—	—

Filing: Form 4 (Insider Transaction) Insider: Walbert Timothy P (Director) Shares: 7,490

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-04

BMRN insider Form 4 filed for equity award, exercise, or tax withholding

Ho Maykin (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	7,490	—	—

Filing: Form 4 (Insider Transaction) Insider: Ho Maykin (Director) Shares: 7,490

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-04

BMRN insider Form 4 filed for equity award, exercise, or tax withholding

HOMBACH ROBERT J. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	7,490	—	—

Filing: Form 4 (Insider Transaction) Insider: HOMBACH ROBERT J. (Director) Shares: 7,490

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-04

BMRN insider Form 4 filed for equity award, exercise, or tax withholding

Enyedy Mark J (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	7,490	—	—

Filing: Form 4 (Insider Transaction) Insider: Enyedy Mark J (Director) Shares: 7,490

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-04

BMRN insider Form 4 filed for equity award, exercise, or tax withholding

Dere Willard H (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	7,490	—	—

Filing: Form 4 (Insider Transaction) Insider: Dere Willard H (Director) Shares: 7,490

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 1 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. BioMarin Pharmaceutical Inc. has 1 such notice in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-02

BMRN Form 144 filed for proposed insider sale by Davis George Eric (17,557 shares) ~$1.16M

Davis George Eric filed a Form 144 with the SEC indicating intent to sell BMRN (BIOMARIN PHARMACEUTICAL INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Davis George Eric Shares: 17,557 Est. Value: $1.16M

View on SEC EDGAR → Open Filing Document →

Material Events 9 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 9 in this period for BioMarin Pharmaceutical Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-06